Kennedy Indsey, Francis Heather, Meng Fanyin, Glaser Shannon, Alpini Gianfranco
Research, Central Texas Veterans Health Care System.
Department of Medicine, Texas A&M Health Science Center, College of Medicine.
Liver Res. 2017 Jun;1(1):34-41. doi: 10.1016/j.livres.2017.03.003. Epub 2017 Apr 26.
Cholangiopathies are a group of rare, devastating diseases that arise from damaged cholangiocytes, the cells that line the intra- and extra-hepatic bile ducts of the biliary epithelium. Cholangiopathies result in significant morbidity and mortality and are a major cause of liver transplantation. A better understanding of the underlying pathogenesis that influences cholangiocyte dysregulation and cholangiopathy progression is necessary, considering the dismal prognosis associated with these diseases. MicroRNAs are a class of small, non-coding RNAs that regulate post-transcriptional mRNA expression of specific genes. The role of microRNAs has expanded to include the initiation and development of many diseases, including cholangiopathies. Understanding microRNA regulation of cholangiopathies may provide diagnostic and therapeutic benefit for these diseases. In this review, the authors primarily focus on studies published within the last five years that help determine the diagnostic and therapeutic potential of microRNAs in cholangiopathies.
胆管病是一组罕见的、具有破坏性的疾病，源于胆管上皮细胞（即衬于肝内和肝外胆管的细胞）受损。胆管病会导致显著的发病率和死亡率，是肝移植的主要原因。鉴于这些疾病预后不佳，有必要更好地了解影响胆管细胞失调和胆管病进展的潜在发病机制。微小RNA是一类小的非编码RNA，可调节特定基因的转录后mRNA表达。微小RNA的作用已扩展到包括许多疾病（包括胆管病）的发生和发展。了解微小RNA对胆管病的调控可能为这些疾病提供诊断和治疗益处。在本综述中，作者主要关注过去五年内发表的有助于确定微小RNA在胆管病中的诊断和治疗潜力的研究。
